{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000125","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.076260+00:00","generated_at":"2026-06-08T05:32:04.606729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Senti Bio Q3 net loss $14.9M; cash $39.4M; Celest partnership up to $156M","bullets":["Net loss $14.9M ($0.34/share) includes non-recurring $21.7M gain and $25.7M impairment from GeneFab transaction.","Cash and short-term investments $39.4M; expects to fund operations into Q4 2024.","SENTI-202 IND on track for clearance Q4 2023; Phase 1 trial for AML expected to start early 2024.","Celest collaboration for SENTI-301A: up to $156M milestones plus tiered royalties; first patient H1 2024 in China.","GeneFab transaction: $37.8M total consideration; $18.9M at closing, $18.9M in installments 2024-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000125","json":"https://secwatch.observer/filing/0001854270-23-000125.json","markdown":"https://secwatch.observer/filing/0001854270-23-000125.md","text":"https://secwatch.observer/filing/0001854270-23-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/0001854270-23-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/snti-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:32:04.606729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0a02b5f1c63459023046f9453804186b3f3d267","claim":"Senti Biosciences, Inc. reported third quarter of 2023 results: net income 14.9, EPS 0.34.","evidence_excerpt":"Net loss was $14.9 million, or $0.34 per basic and diluted share, for the quarter ended September 30, 2023, which included a non-recurring $21.7 million gain from discontinued operations, as well as a non-recurring $25.7 million impairment for leasehold improvements, both related to the GeneFab transaction.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/0001854270-23-000125-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Net income","value":"14.9"},{"label":"EPS","value":"0.34"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}